SlideShare a Scribd company logo
INDIVIDUAL CANCER RISK ASSESSMENTS
USING CONDITIONAL SURVIVAL
Prof. Eric Raymond MD, PhD
Head Medical Oncology @ Paris Saint-Joseph Hospital
Chair of The PAMM Group EORTC
Medical Officer at SCOR – Paris
France
1
Challenges
• The incidence of most cancers has been increasing over the last 50 years, while
progresses in the detection and management of cancers have led to significant
increases in both prevalence and survival
• The number of patients newly diagnosed and those deemed long termcancer
‘survivors’ - patients fit and alive at more than five years after diagnosis - has been
increasing worldwide, yielding newchallenges for insurance companies
• Data in 2014 yielded an overall estimate of about 14.5 million cancer survivors in the United
States(>4% of the US population)
• Current epidemiology trends predict that the number of cancer survivors in the US will
increase by 31% by 2024 (19 millions)
• Long-termsurvivors have been constantly challenging insurance companies for
better coverage, who have adapted in return by offering innovative products and
underwriting approaches for these newclasses of customers
Cancers & Insurances
• Worldwide increase of cancer survivors: increasing needs of insurance
• Allow access to insurance coverage for access to credit to patient with past history of
cancer
• Cover cancer as a critical illness to cover expansive medical care wherever health care is
not mutualized by public services
• Cover income protection
• Cover disability and dependence
• Underwriting cancer has been mainly based on:
• Cancer type
• Staging: TNM or AJCC stage
• Immediate sequelae or morbidities linked to cancer and/or its treatment
• Possibilities of long-term complications from cancer therapy and/or recurrences
• Frequent updates needed to continuously meet scientific and medical progress:
• Difficult to estimate an individual risk based on current medical publications
• Difficult to implement rapidly changing and constantly evolving knowledge - especially
for oncology - at the forefront of medicine
3
4
CANCER : Overall goal
Generate evidence-based information to improve assessments
Develop a mathematical model based on easily obtainable
variables, which can allow an accurate estimate of the excess
mortality rate of these individuals
How to accurately estimate a risk ?
Estimation of Conditional survival
The concept of conditional survival
• Estimation of prognostic at diagnostic is a valuable tool to select the appropriate
treatment strategies ‘chemotherapy, radiotherapy, surgery, targeted agent,
immunotherapy) for individual patients
• TNM, stage, grading classification are routinely used
• Derived Kaplan Meier survival estimate allow to identify groups at specific risk
• We need to understand that the prognostic of individual may evolve over time
(even in high risk patients) as the risk of dying of cancer reduce over time for those
who survive (long termsurvivor are better prognostic group regardless their initial
prognosis)
• Survival estimates need to be reevaluated at various time points after diagnosis to take
into account this paradigm
• This is what we call the estimation of conditional survival (corrected conditional survival
taking further into account the lack of relapse at particular time-points
5
Breast and colon cancers
6
Breast cancer
as a paradigm of a heterogeneous cancer type
Colon cancer
as more homogeneous tumor type
Some of the most frequent tumor types
R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
7
Engineered algorithms that used the SEER data set
20 US states registries on all cancer types
9,675,661 detailed cases of patient with cancer (2016)
Data regularly updated and validated
Algorithm Individual risk assessment
R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
8
Overall versus conditional cancer survival
R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
Breast cancer
Conditional survival appraisal
Mortality estimates according to hormone receptor (HR) expression
10
— The outcome of breast cancer may
vary depending of phenotypic
characteristics:
ØHR positive tumors may have a
better overall prognosis but
keep the same risk of relapse
over time
ØHR negative tumors have a
worst prognosis that is
characterized by a higher risk of
early relapse
but the risk of relapse decreases
over time
R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
T1N1M0 invasive ductal breast cancer
11
Corrected survival
Uncorrected survival
Survival at Diagnosis
HR+ HR-
R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
Colon cancer
Conditional survival appraisal
Conditional survival at 3 years
Correctedsurvival
Uncorrectedsurvival
Survival atDiagnosis
Comparison scoring & KM
pT3N1 grade 3 colon cancer
13R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T
O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
Conclusion
14
• The evaluation of trends in cancer trends and mortality is
an important part of the risk estimation for insurance
companies
• Cancer stands as one of the most prevalent and costly
disease worldwide with increasing number of long
survivors
• Evidence-based estimations of the risk based on large
databases and novel tools are essential to derive fair rating

More Related Content

What's hot

Cancer screening for seniors
Cancer screening for seniorsCancer screening for seniors
Cancer screening for seniors
Robert J Miller MD
 
New Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate CancerNew Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate Cancer
flasco_org
 
DCIS: What You Need to Know
DCIS: What You Need to KnowDCIS: What You Need to Know
DCIS: What You Need to Know
bkling
 
What We Know and Don't Yet Know About DCIS
What We Know and Don't Yet Know About DCISWhat We Know and Don't Yet Know About DCIS
What We Know and Don't Yet Know About DCIS
bkling
 
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MD
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MDGenetics: Beyond BRCA, Reem Saadeh-Haddad, MD
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MD
Ovarian Cancer Research Fund Alliance
 
Gi tumour
Gi tumourGi tumour
Gi tumour
elango mk
 
DCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
DCIS Topic-Driven Round Table: Decision-Making and Treatment ChoicesDCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
DCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
bkling
 
Tumour Agnostic Treatments
Tumour Agnostic TreatmentsTumour Agnostic Treatments
Tumour Agnostic Treatments
Canadian Cancer Survivor Network
 
Effect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidenceEffect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidence
Dave Chase
 
Prostate Cancer Screening
Prostate Cancer ScreeningProstate Cancer Screening
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
Ovarian Cancer Research Fund Alliance
 
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningEvolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
summer elmorshidy
 
Validation of a 46 gene expression signature in early-stage non-small-cell lu...
Validation of a 46 gene expression signature in early-stage non-small-cell lu...Validation of a 46 gene expression signature in early-stage non-small-cell lu...
Validation of a 46 gene expression signature in early-stage non-small-cell lu...
MyriadGenetics
 
Multidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer UnitMultidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer Unit
Europa Uomo EPAD
 
Topic-Driven Round Table on DCIS: What are Your Radiation Options?
Topic-Driven Round Table on DCIS: What are Your Radiation Options?Topic-Driven Round Table on DCIS: What are Your Radiation Options?
Topic-Driven Round Table on DCIS: What are Your Radiation Options?
bkling
 
Cancer etiology
Cancer etiologyCancer etiology
Cancer etiology
Nilesh Kucha
 
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtabaEAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
Dr Ali MUJTABA
 
Oncotype dx
Oncotype dxOncotype dx
Oncotype dx
Abhinav Mutneja
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology Informatics
Warren Kibbe
 

What's hot (20)

Cancer screening for seniors
Cancer screening for seniorsCancer screening for seniors
Cancer screening for seniors
 
New Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate CancerNew Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate Cancer
 
DCIS: What You Need to Know
DCIS: What You Need to KnowDCIS: What You Need to Know
DCIS: What You Need to Know
 
VAR
VARVAR
VAR
 
What We Know and Don't Yet Know About DCIS
What We Know and Don't Yet Know About DCISWhat We Know and Don't Yet Know About DCIS
What We Know and Don't Yet Know About DCIS
 
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MD
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MDGenetics: Beyond BRCA, Reem Saadeh-Haddad, MD
Genetics: Beyond BRCA, Reem Saadeh-Haddad, MD
 
Gi tumour
Gi tumourGi tumour
Gi tumour
 
DCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
DCIS Topic-Driven Round Table: Decision-Making and Treatment ChoicesDCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
DCIS Topic-Driven Round Table: Decision-Making and Treatment Choices
 
Tumour Agnostic Treatments
Tumour Agnostic TreatmentsTumour Agnostic Treatments
Tumour Agnostic Treatments
 
Effect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidenceEffect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidence
 
Prostate Cancer Screening
Prostate Cancer ScreeningProstate Cancer Screening
Prostate Cancer Screening
 
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
Mello Abrams Lecture: Research in Ovarian Cancer, Where Are We Now?, Michael ...
 
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningEvolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
 
Validation of a 46 gene expression signature in early-stage non-small-cell lu...
Validation of a 46 gene expression signature in early-stage non-small-cell lu...Validation of a 46 gene expression signature in early-stage non-small-cell lu...
Validation of a 46 gene expression signature in early-stage non-small-cell lu...
 
Multidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer UnitMultidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer Unit
 
Topic-Driven Round Table on DCIS: What are Your Radiation Options?
Topic-Driven Round Table on DCIS: What are Your Radiation Options?Topic-Driven Round Table on DCIS: What are Your Radiation Options?
Topic-Driven Round Table on DCIS: What are Your Radiation Options?
 
Cancer etiology
Cancer etiologyCancer etiology
Cancer etiology
 
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtabaEAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
 
Oncotype dx
Oncotype dxOncotype dx
Oncotype dx
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology Informatics
 

Similar to 3rd EORTC Cancer Survivorship Summit -

Oncotype dx
Oncotype dxOncotype dx
Oncotype dx
NHS
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
MusaibMushtaq
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
KamelFarag4
 
Tgh talk
Tgh talkTgh talk
Tgh talk
MUCINGroup
 
Screening for carcinoma prostate
Screening for carcinoma prostateScreening for carcinoma prostate
Screening for carcinoma prostatePrakash Hs
 
Geriatric Oncology
Geriatric OncologyGeriatric Oncology
Geriatric Oncology
Camilla Wong
 
EBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptxEBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptx
JerubAlex1
 
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
Paul Dickman
 
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista LemaireProstate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
Niela Valdez
 
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
SSR Institute of International Journal of Life Sciences
 
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...European School of Oncology
 
Point counterpoint in PCa screening
Point counterpoint in PCa screeningPoint counterpoint in PCa screening
Point counterpoint in PCa screeningPatricia Khashayar
 
Low Dose CT Screening for Early Diagnosis of Lung Cancer
Low Dose CT Screening for Early Diagnosis of Lung CancerLow Dose CT Screening for Early Diagnosis of Lung Cancer
Low Dose CT Screening for Early Diagnosis of Lung Cancer
Kue Lee
 
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015Landi F. Valutazione del Geriatric Assessment. ASMaD 2015
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015Gianfranco Tammaro
 
Joseph Gligorov : Breast Cancer late metastasis
Joseph Gligorov  : Breast Cancer late metastasis Joseph Gligorov  : Breast Cancer late metastasis
Joseph Gligorov : Breast Cancer late metastasis breastcancerupdatecongress
 
Psa guideline exercise
Psa guideline exercisePsa guideline exercise
Psa guideline exerciseJohn Voss
 
H2O World - H2O for Genomics with Hussam Al-Deen Ashab
H2O World - H2O for Genomics with Hussam Al-Deen AshabH2O World - H2O for Genomics with Hussam Al-Deen Ashab
H2O World - H2O for Genomics with Hussam Al-Deen Ashab
Sri Ambati
 
Tumor markers,AFP.CEA
Tumor markers,AFP.CEATumor markers,AFP.CEA
Tumor markers,AFP.CEA
Prashant Sharma
 
A convenient clinical nomogram for small intestine adenocarcinoma
A convenient clinical nomogram for small intestine adenocarcinomaA convenient clinical nomogram for small intestine adenocarcinoma
A convenient clinical nomogram for small intestine adenocarcinoma
nguyên anh doanh
 

Similar to 3rd EORTC Cancer Survivorship Summit - (20)

Oncotype dx
Oncotype dxOncotype dx
Oncotype dx
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
 
Tgh talk
Tgh talkTgh talk
Tgh talk
 
Screening for carcinoma prostate
Screening for carcinoma prostateScreening for carcinoma prostate
Screening for carcinoma prostate
 
Geriatric Oncology
Geriatric OncologyGeriatric Oncology
Geriatric Oncology
 
EBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptxEBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptx
 
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
Making Cancer Survival Statistics More Relevant for Clinicians, Patients, and...
 
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista LemaireProstate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
 
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
Histopathological_Correlation_ER_PR_HER2_Neu_Receptor_Breast_Carcinoma_Progno...
 
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
 
Point counterpoint in PCa screening
Point counterpoint in PCa screeningPoint counterpoint in PCa screening
Point counterpoint in PCa screening
 
Low Dose CT Screening for Early Diagnosis of Lung Cancer
Low Dose CT Screening for Early Diagnosis of Lung CancerLow Dose CT Screening for Early Diagnosis of Lung Cancer
Low Dose CT Screening for Early Diagnosis of Lung Cancer
 
Prostate cancer (screening)
Prostate cancer (screening)Prostate cancer (screening)
Prostate cancer (screening)
 
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015Landi F. Valutazione del Geriatric Assessment. ASMaD 2015
Landi F. Valutazione del Geriatric Assessment. ASMaD 2015
 
Joseph Gligorov : Breast Cancer late metastasis
Joseph Gligorov  : Breast Cancer late metastasis Joseph Gligorov  : Breast Cancer late metastasis
Joseph Gligorov : Breast Cancer late metastasis
 
Psa guideline exercise
Psa guideline exercisePsa guideline exercise
Psa guideline exercise
 
H2O World - H2O for Genomics with Hussam Al-Deen Ashab
H2O World - H2O for Genomics with Hussam Al-Deen AshabH2O World - H2O for Genomics with Hussam Al-Deen Ashab
H2O World - H2O for Genomics with Hussam Al-Deen Ashab
 
Tumor markers,AFP.CEA
Tumor markers,AFP.CEATumor markers,AFP.CEA
Tumor markers,AFP.CEA
 
A convenient clinical nomogram for small intestine adenocarcinoma
A convenient clinical nomogram for small intestine adenocarcinomaA convenient clinical nomogram for small intestine adenocarcinoma
A convenient clinical nomogram for small intestine adenocarcinoma
 

More from Prof. Eric Raymond Oncologie Medicale

Impact of the COVID‑19 Outbreak on the Management of Patients with Cancer
Impact of the COVID‑19 Outbreak on the Management of Patients with CancerImpact of the COVID‑19 Outbreak on the Management of Patients with Cancer
Impact of the COVID‑19 Outbreak on the Management of Patients with Cancer
Prof. Eric Raymond Oncologie Medicale
 
Post covid-19-outbreak impact on cancer mortality
Post covid-19-outbreak impact on cancer mortalityPost covid-19-outbreak impact on cancer mortality
Post covid-19-outbreak impact on cancer mortality
Prof. Eric Raymond Oncologie Medicale
 
Etre cancerologue en period covid
Etre cancerologue en period covidEtre cancerologue en period covid
Etre cancerologue en period covid
Prof. Eric Raymond Oncologie Medicale
 
Oncovid - Cancer versus COVID-19
Oncovid - Cancer versus COVID-19Oncovid - Cancer versus COVID-19
Oncovid - Cancer versus COVID-19
Prof. Eric Raymond Oncologie Medicale
 
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
Prof. Eric Raymond Oncologie Medicale
 
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
Prof. Eric Raymond Oncologie Medicale
 
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Prof. Eric Raymond Oncologie Medicale
 
Le Quotidien du Médecin spécial cancérologie 2019
Le Quotidien du Médecin spécial cancérologie 2019Le Quotidien du Médecin spécial cancérologie 2019
Le Quotidien du Médecin spécial cancérologie 2019
Prof. Eric Raymond Oncologie Medicale
 
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
Prof. Eric Raymond Oncologie Medicale
 
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
Prof. Eric Raymond Oncologie Medicale
 
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETsENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
Prof. Eric Raymond Oncologie Medicale
 
Phase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meetingPhase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meeting
Prof. Eric Raymond Oncologie Medicale
 
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell linesInvolvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Prof. Eric Raymond Oncologie Medicale
 
HCC Transgenic tumor model
HCC Transgenic tumor modelHCC Transgenic tumor model
HCC Transgenic tumor model
Prof. Eric Raymond Oncologie Medicale
 
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
Prof. Eric Raymond Oncologie Medicale
 
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric RaymondDevelopment of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Prof. Eric Raymond Oncologie Medicale
 
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric RaymondPerspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
Prof. Eric Raymond Oncologie Medicale
 
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
Prof. Eric Raymond Oncologie Medicale
 
Prise en charge du patient en cours de traitement oncologique pour une interv...
Prise en charge du patient en cours de traitement oncologique pour une interv...Prise en charge du patient en cours de traitement oncologique pour une interv...
Prise en charge du patient en cours de traitement oncologique pour une interv...
Prof. Eric Raymond Oncologie Medicale
 
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Prof. Eric Raymond Oncologie Medicale
 

More from Prof. Eric Raymond Oncologie Medicale (20)

Impact of the COVID‑19 Outbreak on the Management of Patients with Cancer
Impact of the COVID‑19 Outbreak on the Management of Patients with CancerImpact of the COVID‑19 Outbreak on the Management of Patients with Cancer
Impact of the COVID‑19 Outbreak on the Management of Patients with Cancer
 
Post covid-19-outbreak impact on cancer mortality
Post covid-19-outbreak impact on cancer mortalityPost covid-19-outbreak impact on cancer mortality
Post covid-19-outbreak impact on cancer mortality
 
Etre cancerologue en period covid
Etre cancerologue en period covidEtre cancerologue en period covid
Etre cancerologue en period covid
 
Oncovid - Cancer versus COVID-19
Oncovid - Cancer versus COVID-19Oncovid - Cancer versus COVID-19
Oncovid - Cancer versus COVID-19
 
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
Moscow summit 2020 : seeking for the cure of primary and secondary liver mali...
 
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
Anniversaire de L'institut des Vaisseaux et du Sang (IVS)
 
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
 
Le Quotidien du Médecin spécial cancérologie 2019
Le Quotidien du Médecin spécial cancérologie 2019Le Quotidien du Médecin spécial cancérologie 2019
Le Quotidien du Médecin spécial cancérologie 2019
 
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
IATTGI Lecture on hepatocellular carcinoma for the multidisciplinary oncology...
 
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
IATTGI Educational Lecture on pancreatic cancer by Eric Raymond in Buenos Air...
 
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETsENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
ENETS 2019 Post-graduate Course on Novel Antiangiogenics in the Field of NETs
 
Phase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meetingPhase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meeting
 
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell linesInvolvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell lines
 
HCC Transgenic tumor model
HCC Transgenic tumor modelHCC Transgenic tumor model
HCC Transgenic tumor model
 
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
Programme Octobre Rose - la semaine du 8 au 12 octobre 2018
 
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric RaymondDevelopment of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
 
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric RaymondPerspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
 
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
 
Prise en charge du patient en cours de traitement oncologique pour une interv...
Prise en charge du patient en cours de traitement oncologique pour une interv...Prise en charge du patient en cours de traitement oncologique pour une interv...
Prise en charge du patient en cours de traitement oncologique pour une interv...
 
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
 

Recently uploaded

263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 

Recently uploaded (20)

263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 

3rd EORTC Cancer Survivorship Summit -

  • 1. INDIVIDUAL CANCER RISK ASSESSMENTS USING CONDITIONAL SURVIVAL Prof. Eric Raymond MD, PhD Head Medical Oncology @ Paris Saint-Joseph Hospital Chair of The PAMM Group EORTC Medical Officer at SCOR – Paris France 1
  • 2. Challenges • The incidence of most cancers has been increasing over the last 50 years, while progresses in the detection and management of cancers have led to significant increases in both prevalence and survival • The number of patients newly diagnosed and those deemed long termcancer ‘survivors’ - patients fit and alive at more than five years after diagnosis - has been increasing worldwide, yielding newchallenges for insurance companies • Data in 2014 yielded an overall estimate of about 14.5 million cancer survivors in the United States(>4% of the US population) • Current epidemiology trends predict that the number of cancer survivors in the US will increase by 31% by 2024 (19 millions) • Long-termsurvivors have been constantly challenging insurance companies for better coverage, who have adapted in return by offering innovative products and underwriting approaches for these newclasses of customers
  • 3. Cancers & Insurances • Worldwide increase of cancer survivors: increasing needs of insurance • Allow access to insurance coverage for access to credit to patient with past history of cancer • Cover cancer as a critical illness to cover expansive medical care wherever health care is not mutualized by public services • Cover income protection • Cover disability and dependence • Underwriting cancer has been mainly based on: • Cancer type • Staging: TNM or AJCC stage • Immediate sequelae or morbidities linked to cancer and/or its treatment • Possibilities of long-term complications from cancer therapy and/or recurrences • Frequent updates needed to continuously meet scientific and medical progress: • Difficult to estimate an individual risk based on current medical publications • Difficult to implement rapidly changing and constantly evolving knowledge - especially for oncology - at the forefront of medicine 3
  • 4. 4 CANCER : Overall goal Generate evidence-based information to improve assessments Develop a mathematical model based on easily obtainable variables, which can allow an accurate estimate of the excess mortality rate of these individuals How to accurately estimate a risk ? Estimation of Conditional survival
  • 5. The concept of conditional survival • Estimation of prognostic at diagnostic is a valuable tool to select the appropriate treatment strategies ‘chemotherapy, radiotherapy, surgery, targeted agent, immunotherapy) for individual patients • TNM, stage, grading classification are routinely used • Derived Kaplan Meier survival estimate allow to identify groups at specific risk • We need to understand that the prognostic of individual may evolve over time (even in high risk patients) as the risk of dying of cancer reduce over time for those who survive (long termsurvivor are better prognostic group regardless their initial prognosis) • Survival estimates need to be reevaluated at various time points after diagnosis to take into account this paradigm • This is what we call the estimation of conditional survival (corrected conditional survival taking further into account the lack of relapse at particular time-points 5
  • 6. Breast and colon cancers 6 Breast cancer as a paradigm of a heterogeneous cancer type Colon cancer as more homogeneous tumor type Some of the most frequent tumor types R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 7. 7 Engineered algorithms that used the SEER data set 20 US states registries on all cancer types 9,675,661 detailed cases of patient with cancer (2016) Data regularly updated and validated Algorithm Individual risk assessment R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 8. 8 Overall versus conditional cancer survival R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 10. Mortality estimates according to hormone receptor (HR) expression 10 — The outcome of breast cancer may vary depending of phenotypic characteristics: ØHR positive tumors may have a better overall prognosis but keep the same risk of relapse over time ØHR negative tumors have a worst prognosis that is characterized by a higher risk of early relapse but the risk of relapse decreases over time R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 11. T1N1M0 invasive ductal breast cancer 11 Corrected survival Uncorrected survival Survival at Diagnosis HR+ HR- R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 13. Conditional survival at 3 years Correctedsurvival Uncorrectedsurvival Survival atDiagnosis Comparison scoring & KM pT3N1 grade 3 colon cancer 13R e f. S C O R U N D E R W R IT IN G C A N C E R P R O JE C T O P T IM IZ IN G IN D IV ID U A L C A N C E R R A T IN G A S S E S S M E N T S B A S E D O N U P D A T E D A L G O R IT H M S - S C O R JU N E 2 0 1 7
  • 14. Conclusion 14 • The evaluation of trends in cancer trends and mortality is an important part of the risk estimation for insurance companies • Cancer stands as one of the most prevalent and costly disease worldwide with increasing number of long survivors • Evidence-based estimations of the risk based on large databases and novel tools are essential to derive fair rating